RAD51 and B-cell chronic lymphocytic leukemia: Collectively, our results revealed that NUSAP1 served as an oncogene leading to activate DNA damage repair pathway by binding with RAD51, which providing theoretical basis for novel molecular markers and targeted therapy in CLL.